Types of Oncologists: Medical, Surgical, and Radiation

Oncology is not practiced by a single type of physician. Cancer care is divided among three foundational specialist categories — medical, surgical, and radiation oncologists — each defined by distinct training pathways, treatment tools, and clinical responsibilities. Understanding these divisions clarifies how cancer treatment teams are assembled, how referrals are routed, and why a patient with a single diagnosis may be seen by physicians from more than one specialty.

Definition and Scope

The three core oncologist types are formally recognized by the American Board of Medical Specialties (ABMS), which certifies each through separate member boards. Medical oncology falls under the American Board of Internal Medicine (ABIM), surgical oncology under the American Board of Surgery (ABS), and radiation oncology under the American Board of Radiology (ABR). This tripartite structure reflects the three mechanistic approaches to treating solid tumors and hematologic malignancies: systemic therapy, physical removal, and energy-based destruction of tissue.

The American Cancer Society and the National Cancer Institute (NCI) both use this three-category framework in patient-facing literature, reinforcing it as the standard clinical taxonomy rather than an informal designation. The broader landscape of subspecialties of oncology extends beyond these three into pediatric oncology, neuro-oncology, and gynecologic oncology, but all of those subspecialists share the foundational training of one of the three core types.

The regulatory context for oncology — including FDA drug approvals, state licensure requirements, and accreditation standards from the American College of Surgeons Commission on Cancer — applies differently across these three categories because each specialty uses a distinct class of treatment modality.

How It Works

Each specialist type operates within a defined scope that is shaped by training duration, board requirements, and treatment modality.

Medical Oncologists

Medical oncologists complete internal medicine residency (3 years) followed by a fellowship in hematology-oncology or oncology alone (2–3 years), as structured under ABIM guidelines. Their primary tools are systemic agents: chemotherapy, targeted therapy, immunotherapy, and hormone therapy. Medical oncologists manage treatment sequencing for the majority of metastatic cancers and coordinate the overall treatment plan in multidisciplinary teams. For hematologic cancers such as leukemia and lymphoma, a hematologist-oncologist — a physician board-certified in both hematology and oncology — takes the primary role.

Surgical Oncologists

Surgical oncologists complete general surgery residency (5 years) and a fellowship in surgical oncology (2 years), per ABS standards. The defining scope is operative: biopsy, resection, cytoreductive surgery, and surgical staging. Surgical oncologists differ from general surgeons in that they are specifically trained to achieve oncologically adequate margins and to perform complex resections such as Whipple procedures for pancreatic cancer or sentinel lymph node biopsies for breast cancer. The ABS fellowship in complex general surgical oncology specifically requires operative volume thresholds to qualify for certification. Full detail on the training pathway is covered at surgical oncology fellowship.

Radiation Oncologists

Radiation oncologists complete a dedicated 4-year residency in radiation oncology accredited by the Accreditation Council for Graduate Medical Education (ACGME), followed by ABR board certification. They design and deliver ionizing radiation to tumor targets using technologies including external beam radiation therapy (EBRT), stereotactic body radiation therapy (SBRT), and brachytherapy. Radiation planning — called dosimetry — is performed collaboratively with medical physicists and dosimetrists, with the radiation oncologist holding clinical responsibility for the treatment plan. The full clinical picture of this modality is described at radiation therapy.

A structured comparison of the three roles:

  1. Treatment tool: Medical = systemic drugs; Surgical = operative intervention; Radiation = ionizing energy
  2. Primary training board: ABIM; ABS; ABR
  3. Fellowship length: 2–3 years post-residency; 2 years post-residency; 4-year dedicated residency
  4. Cancer-type leadership: Metastatic/hematologic disease; Resectable solid tumors; Localized tumors requiring non-surgical destruction
  5. Typical care setting: Infusion clinic, outpatient office; Operating room, inpatient surgical unit; Radiation treatment center

Common Scenarios

In clinical practice, these specialists rarely operate in complete isolation. Multidisciplinary tumor boards — which the Commission on Cancer (CoC) of the American College of Surgeons requires at accredited cancer centers — bring all three types together to develop consensus treatment recommendations.

A patient diagnosed with lung cancer may require evaluation by a surgical oncologist to assess resectability, a radiation oncologist if surgery is not indicated or if adjuvant radiation is planned, and a medical oncologist to manage chemotherapy or immunotherapy before or after surgery. A patient with prostate cancer presents a classic scenario where the division of labor between radiation oncology and surgical oncology is a primary clinical decision point, with medical oncology entering the picture at the metastatic stage.

For skin cancer, a surgical oncologist typically manages primary resection of melanoma, while a medical oncologist takes over systemic management for stage III or IV disease. The overview of oncology practice models at this site details how these specialists are organized institutionally.

Decision Boundaries

The determination of which oncologist type leads a patient's care follows clinical logic anchored in tumor characteristics, stage, and treatment intent.

Surgery as primary modality is appropriate when a solid tumor is localized, the patient is medically fit for anesthesia, and complete resection (R0 margin) is achievable. The National Comprehensive Cancer Network (NCCN) publishes disease-specific guidelines — available at NCCN.org — that define resectability criteria by tumor type.

Radiation as primary or adjuvant modality is used when tumor location makes surgery high-risk (e.g., base-of-skull tumors), when organ preservation is the clinical goal, or when residual microscopic disease remains after surgery. SBRT delivers doses in 3–5 fractions to small, well-defined targets with sub-centimeter precision.

Medical oncology as primary applies when disease is systemic or metastatic, when no surgical target exists, or when the cancer type (e.g., lymphoma, small cell lung cancer) responds primarily to systemic agents rather than local therapy.

At the boundaries — locally advanced disease, borderline resectable tumors, oligometastatic disease — all three specialties contribute to the decision. These cases are precisely where multidisciplinary tumor boards generate the most clinical value. A broader orientation to the field is available at the oncology authority home.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)